Delay of treatment change following objective progression on first-line erlotinib in EGFR-mutant lung cancer

BACKGROUND: Erlotinib is a highly active EGFR kinase inhibitor approved for first-line use in lung cancers harboring EGFR mutations. Anecdotal experience suggests this drug may provide continued disease control following objective progression of disease (PD), however this has not been systematically...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Lo, Peter C., Dahlberg, Suzanne E., Nishino, Mizuki, Johnson, Bruce E., Sequist, Lecia V., Jackman, David M., Jänne, Pasi A, Oxnard, Geoffrey R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4525718/
https://ncbi.nlm.nih.gov/pubmed/25876525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29397
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados